- The European Commission (EC) has granted marketing authorization for Seagen's (NASDAQ:SGEN) Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
- TUKYSA is an oral, small molecule tyrosine kinase inhibitor (TKI) of HER2, a protein that contributes to cancer cell growth.
- The EMA's advisory group adopted a positive opinion for Tukysa in December 2020.